$0.45
1.38% today
Nasdaq, Apr 04, 09:17 pm CET
ISIN
US5288723027
Symbol
LXRX
Sector
Industry

Lexicon Pharmaceuticals, Inc. Stock price

$0.44
+0.15 51.47% 1M
-1.17 72.47% 6M
-0.30 39.99% YTD
-1.60 78.27% 1Y
-2.08 82.41% 3Y
-1.32 74.82% 5Y
-6.27 93.40% 10Y
Nasdaq, Closing price Thu, Apr 03 2025
-0.06 11.91%
ISIN
US5288723027
Symbol
LXRX
Sector
Industry

Key metrics

Market capitalization $160.21m
Enterprise Value $28.32m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 0.91
P/S ratio (TTM) P/S ratio 5.15
P/B ratio (TTM) P/B ratio 1.10
Revenue growth (TTM) Revenue growth 2,479.34%
Revenue (TTM) Revenue $31.08m
EBIT (operating result TTM) EBIT $-188.22m
Free Cash Flow (TTM) Free Cash Flow $-181.12m
Cash position $237.96m
EPS (TTM) EPS $-0.64
P/E forward negative
P/S forward 17.15
EV/Sales forward 3.03
Short interest 24.09%
Show more

Is Lexicon Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Lexicon Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Lexicon Pharmaceuticals, Inc. forecast:

3x Buy
50%
3x Hold
50%

Analyst Opinions

6 Analysts have issued a Lexicon Pharmaceuticals, Inc. forecast:

Buy
50%
Hold
50%

Financial data from Lexicon Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
31 31
2,469% 2,469%
100%
- Direct Costs 1.15 1.15
80% 80%
4%
30 30
5,151% 5,151%
96%
- Selling and Administrative Expenses 135 135
19% 19%
434%
- Research and Development Expense 83 83
42% 42%
267%
-188 -188
10% 10%
-604%
- Depreciation and Amortization 0.53 0.53
4% 4%
2%
EBIT (Operating Income) EBIT -188 -188
10% 10%
-606%
Net Profit -200 -200
14% 14%
-645%

In millions USD.

Don't miss a Thing! We will send you all news about Lexicon Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Lexicon Pharmaceuticals, Inc. Stock News

Neutral
GlobeNewsWire
2 days ago
THE WOODLANDS, Texas, April 02, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a presentation at the 24th Annual Needham Virtual Healthcare Conference 2025 on Wednesday, April 9, at 8:00 a.m. ET. The live event and a replay of the presentation can be accessed via the Events page of the Company's website at https:...
Positive
Market Watch
7 days ago
Lexicon Pharmaceuticals shares jumped nearly 75% in early trading Friday after the biopharmaceutical company inked a license agreement potentially worth $1 billion with Danish drug maker Novo Nordisk.
Neutral
GlobeNewsWire
7 days ago
Lexicon eligible to receive up to $1 billion in upfront and development, regulatory and sales milestone payments, including $75 million in upfront and near-term milestone payments Lexicon eligible to receive up to $1 billion in upfront and development, regulatory and sales milestone payments, including $75 million in upfront and near-term milestone payments
More Lexicon Pharmaceuticals, Inc. News

Company Profile

Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include XERMELO, Zynquista, and LX9211. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.

Head office United States
CEO Michael Exton
Employees 103
Founded 1995
Website www.lexpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today